{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=dextromethorphan%2Fquinidine",
    "query": {
      "intervention": "dextromethorphan/quinidine"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 27,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=dextromethorphan%2Fquinidine&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-04T16:57:44.175Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00573443",
      "title": "Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pseudobulbar Affect (PBA)"
      ],
      "interventions": [
        {
          "name": "dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg",
          "type": "DRUG"
        },
        {
          "name": "dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Avanir Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 326,
      "start_date": "2007-12",
      "completion_date": "2009-09",
      "has_results": true,
      "last_update_posted_date": "2017-04-12",
      "last_synced_at": "2026-09-04T16:57:44.175Z",
      "location_count": 45,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Anaheim, California + 39 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00573443"
    },
    {
      "nct_id": "NCT02442778",
      "title": "Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Participants With Dementia of the Alzheimer's Type",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Agitation in Participants With Dementia of the Alzheimer's Type"
      ],
      "interventions": [
        {
          "name": "AVP-786-18",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "AVP-786-28",
          "type": "DRUG"
        },
        {
          "name": "AVP-786-42.63",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "50 Years to 90 Years"
      },
      "enrollment_count": 522,
      "start_date": "2015-11-11",
      "completion_date": "2019-09-09",
      "has_results": true,
      "last_update_posted_date": "2022-09-09",
      "last_synced_at": "2026-09-04T16:57:44.175Z",
      "location_count": 79,
      "location_summary": "Chandler, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 55 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02442778"
    },
    {
      "nct_id": "NCT02496039",
      "title": "Effectiveness, Safety, and Health-Related Outcomes of NUEDEXTA® in Nursing Home Patients With Pseudobulbar Affect (PBA)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pseudobulbar Affect (Involuntary Laughing and/or Crying)"
      ],
      "interventions": [
        {
          "name": "NUEDEXTA®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Avanir Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 5,
      "start_date": "2015-09",
      "completion_date": "2016-05",
      "has_results": true,
      "last_update_posted_date": "2017-07-03",
      "last_synced_at": "2026-09-04T16:57:44.175Z",
      "location_count": 2,
      "location_summary": "Miami, Florida • Centerville, Ohio",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Centerville",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02496039"
    },
    {
      "nct_id": "NCT02153502",
      "title": "Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Depressive Disorder, Treatment-Resistant"
      ],
      "interventions": [
        {
          "name": "AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 206,
      "start_date": "2014-07-01",
      "completion_date": "2016-02-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-13",
      "last_synced_at": "2026-09-04T16:57:44.175Z",
      "location_count": 32,
      "location_summary": "Birmingham, Alabama • Bellflower, California • Costa Mesa, California + 26 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Bellflower",
          "state": "California"
        },
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02153502"
    },
    {
      "nct_id": "NCT00050232",
      "title": "Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "AVP-923",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Avanir Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "68 Years",
        "sex": "ALL",
        "summary": "18 Years to 68 Years"
      },
      "enrollment_count": 96,
      "start_date": "2002-12",
      "completion_date": "2004-06",
      "has_results": false,
      "last_update_posted_date": "2016-07-14",
      "last_synced_at": "2026-09-04T16:57:44.175Z",
      "location_count": 20,
      "location_summary": "Phoenix, Arizona • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 17 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Elk Grove Village",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00050232"
    },
    {
      "nct_id": "NCT01767129",
      "title": "Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dyskinesia",
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "AVP-923-45",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Avanir Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "30 Years to 80 Years"
      },
      "enrollment_count": 14,
      "start_date": "2013-10-16",
      "completion_date": "2015-02-05",
      "has_results": true,
      "last_update_posted_date": "2022-04-29",
      "last_synced_at": "2026-09-04T16:57:44.175Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois • Portland, Oregon",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01767129"
    },
    {
      "nct_id": "NCT02442765",
      "title": "Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Agitation in Patients With Dementia of the Alzheimer's Type"
      ],
      "interventions": [
        {
          "name": "AVP-786",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "50 Years to 90 Years"
      },
      "enrollment_count": 387,
      "start_date": "2015-07-23",
      "completion_date": "2019-02-27",
      "has_results": true,
      "last_update_posted_date": "2023-02-13",
      "last_synced_at": "2026-09-04T16:57:44.175Z",
      "location_count": 111,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 78 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02442765"
    },
    {
      "nct_id": "NCT02402595",
      "title": "Drug Interaction Study Between AVP-923 and Itraconazole and Between AVP-786 and Itraconazole in Healthy Adult Subejcts",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "AVP-923",
          "type": "DRUG"
        },
        {
          "name": "AVP-786",
          "type": "DRUG"
        },
        {
          "name": "Itraconazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 24,
      "start_date": "2015-03-01",
      "completion_date": "2015-07-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-28",
      "last_synced_at": "2026-09-04T16:57:44.175Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02402595"
    },
    {
      "nct_id": "NCT02176018",
      "title": "Nuedexta for the Prevention and Modification of Disease Progression in Episodic Migraine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Episodic Migraine"
      ],
      "interventions": [
        {
          "name": "Dextromethorphan and quinidine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cady, Roger, M.D.",
      "sponsor_class": "INDIV",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 76,
      "start_date": "2014-08",
      "completion_date": "2017-03",
      "has_results": true,
      "last_update_posted_date": "2018-04-03",
      "last_synced_at": "2026-09-04T16:57:44.175Z",
      "location_count": 5,
      "location_summary": "Rockford, Illinois • Ridgeland, Mississippi • City of Saint Peters, Missouri + 2 more",
      "locations": [
        {
          "city": "Rockford",
          "state": "Illinois"
        },
        {
          "city": "Ridgeland",
          "state": "Mississippi"
        },
        {
          "city": "City of Saint Peters",
          "state": "Missouri"
        },
        {
          "city": "Springfield",
          "state": "Missouri"
        },
        {
          "city": "Plainview",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02176018"
    },
    {
      "nct_id": "NCT00056524",
      "title": "Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer's Disease",
        "Stroke",
        "Parkinson's Disease",
        "Traumatic Brain Injury"
      ],
      "interventions": [
        {
          "name": "AVP-923",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Avanir Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 600,
      "start_date": "2003-02",
      "completion_date": "2007-06",
      "has_results": false,
      "last_update_posted_date": "2016-07-14",
      "last_synced_at": "2026-09-04T16:57:44.175Z",
      "location_count": 39,
      "location_summary": "Phoenix, Arizona • La Jolla, California • Los Angeles, California + 31 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Darien",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00056524"
    }
  ]
}